HIV Archives – Page 25 of 90 – Treatment Action Group

Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy

March 5, 2018
Chad Cipiti

Introduction For many HIV-positive people—particularly those who initiate treatment soon after infection—combination antiretroviral therapy (ART) is associated with robust improvements in CD4+ T cell counts, enhanced immune function, and a life expectancy comparable to that of similar HIV-negative individuals. But a…

It’s Time to Deliver – Including Pregnant and Lactating Women in Clinical Research

February 6, 2018
Chad Cipiti

Pregnant women have frequently been excluded from or de-prioritized in clinical research initiatives due to a multitude of factors, such as the complex physiology of pregnant women, the risk studies may pose to the fetus, and the classification of pregnant…

Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV

February 1, 2018
Chad Cipiti

The purpose of this Training Manual is to provide information for you and your community. This information can be used to advocate for access to prevention and diagnosis of, and care and treatment for, hepatitis C virus (HCV). The manual is written by and for people who are not medical specialists. We’re treatment activists who learned about HCV because it was a problem for people in our communities.

Letter to Gilead Sciences Opposing Unethical Patient Assistance Program Policy for Truvada for Postexposure Prophylaxis

January 25, 2018
Chad Cipiti

Gilead Sciences is limiting access to Truvada as a component of nonoccupational postexposure prophylaxis (nPEP) through its patient assistance program to once in a lifetime, with hardship review criteria and processes for subsequent prescriptions that have not been clearly articulated and are likely a considerable barrier to nPEP by uninsured and underinsured U.S. residents.

TAG Mourns the Loss of Mathilde Krim, PhD

January 16, 2018
Chad Cipiti

TAG mourns the loss of an inspirational, tireless, catalytic leader of our movement. Dr. Krim understood the gravity of the epidemic, in its earliest and darkest days, and was driven by her own remarkable intelligence, fierce commitment to civil rights and social justice, extraordinary social and political networks, and true grit to galvanize funders, scientists, policy leaders, and activists toward a single cause: ending HIV and AIDS as a threat to humanity.

TAG Statement to Human Rights Council on Human Rights Concerns in the UAE

December 13, 2017
Chad Cipiti

TAG participated in a hearing in Geneva, Switzerland to brief members of the Human Rights Council on human rights concerns in the United Arab Emirates (UAE).

Story: Cancer Drug Leads to ‘Drastic Decrease’ in HIV Infection in Lung Cancer Patient

December 10, 2017
Dorrit Walsh

November – December 2017 Examples of media coverage: Lung cancer drug may be early clue in hunt for HIV cure – The Independent, November 30, 2017 Cancer drug offers tantalising hope for HIV cure – The Guardian, November 30, 2017…

Suboptimal Immune Recovery on Antiretroviral Therapy: Causes, Consequences, and the Search for Solutions

November 30, 2017
Chad Cipiti

On November 29, 2017, Treatment Action Group (TAG) hosted a webinar on suboptimal immune recovery despite HIV suppression by antiretroviral therapy. Presented by Richard Jefferys, TAG’s Basic Science, Vaccines and Cure Project Director, the webinar reviewed the possible causes and…

End the Epidemic Resources: Southern States EtE Meeting Summary and FAQs

November 1, 2017
Chad Cipiti

Now is the time to end the HIV/AIDS epidemic in America’s southern states. Over the past four years, innovative Ending the Epidemic (EtE) plans have emerged in several jurisdictions across the nation following New York’s 2014 announcement that it will…

US Health & Human Services (HHS) Strategic Plan FY 2018-2022: TAG Comments to the Assistant Secretary for Planning and Evaluation

October 27, 2017
Chad Cipiti

TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.